Viracta Therapeutics Stock Price on December 17, 2024
| VIRX Stock | USD 0.16 0.08 33.33% |
Below is the normalized historical share price chart for Viracta Therapeutics extending back to September 27, 2005. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Viracta Therapeutics stands at 0.16, as last reported on the 29th of December, with the highest price reaching 0.21 and the lowest price hitting 0.15 during the day.
If you're considering investing in Viracta Stock, it is important to understand the factors that can impact its price. Viracta Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0464, which indicates the firm had a -0.0464% return per unit of risk over the last 3 months. Viracta Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Viracta Therapeutics' Coefficient Of Variation of (2,226), variance of 45.15, and Risk Adjusted Performance of (0.03) to confirm the risk estimate we provide.
At this time, Viracta Therapeutics' Total Stockholder Equity is fairly stable compared to the past year. Common Stock Total Equity is likely to rise to 4,956 in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 54.4 M in 2024. . Price To Sales Ratio is likely to drop to 5.90 in 2024. Price Earnings Ratio is likely to drop to -0.45 in 2024. Viracta Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 27th of September 2005 | 200 Day MA 0.4881 | 50 Day MA 0.1916 | Beta 0.299 |
Viracta |
Sharpe Ratio = -0.0464
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VIRX |
Estimated Market Risk
| 6.78 actual daily | 60 60% of assets are less volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Viracta Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viracta Therapeutics by adding Viracta Therapeutics to a well-diversified portfolio.
Price Book 3.0028 | Book Value 0.329 | Enterprise Value 2.1 M | Enterprise Value Ebitda (0.48) | Shares Float 24.8 M |
Related Headline
Tenaya Therapeutics Headline on 17th of December 2024
Tenaya Therapeutics Reports Promising Early Data from MyPEAK... by finance.yahoo.com
TN-201 Well Tolerated at 3E13 vgkg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year Circulating Biomarkers and Other Clinical Measures Mostly Remained Stable or Improved from Baseline Tenaya Management to Host a Webcast Conference Call Today at 800 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 -- Tenaya Therapeutics, Inc. , a c
Viracta Therapeutics Valuation on December 17, 2024
It is possible to determine the worth of Viracta Therapeutics on a given historical date. On December 17, 2024 Viracta was worth 0.21 at the beginning of the trading date compared to the closed value of 0.22. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Viracta Therapeutics stock. Still, in general, we apply an absolute valuation method to find Viracta Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Viracta Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Viracta Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 0.20 | 0.22 | 0.18 | 0.21 | 1,221,933 | |
12/17/2024 | 0.21 | 0.22 | 0.19 | 0.22 | 750,431 |
| 0.21 | 0.23 | 0.21 | 0.21 | 1,086,018 |
| Backtest Viracta Therapeutics | | | Viracta Therapeutics History | | | Viracta Therapeutics Valuation | Previous | Next |
Viracta Therapeutics Trading Date Momentum on December 17, 2024
| On December 18 2024 Viracta Therapeutics was traded for 0.21 at the closing time. The top price for the day was 0.23 and the lowest listed price was 0.21 . The trading volume for the day was 1.1 M. The trading history from December 18, 2024 was a factor to the next trading day price decrease. The trading price change against the next closing price was 4.55% . The trading price change against the current closing price is 9.09% . |
Viracta Therapeutics Fundamentals Correlations and Trends
By evaluating Viracta Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Viracta Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Viracta financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Viracta Therapeutics Stock history
Viracta Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Viracta is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Viracta Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Viracta Therapeutics stock prices may prove useful in developing a viable investing in Viracta Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 38.6 M | 40.6 M | |
| Net Loss | -44.3 M | -46.5 M |
Viracta Therapeutics Quarterly Net Working Capital |
|
Viracta Therapeutics Stock Technical Analysis
Viracta Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Viracta Therapeutics Period Price Range
Low | December 29, 2024
| High |
0.00 | 0.00 |
Viracta Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Viracta Therapeutics December 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Viracta Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Viracta Therapeutics shares will generate the highest return on investment. By undertsting and applying Viracta Therapeutics stock market strength indicators, traders can identify Viracta Therapeutics entry and exit signals to maximize returns
Viracta Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Viracta Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Viracta Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Viracta to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.34) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.